New Vision Wins Another Chance to Defend Gaming Patents Following Arthrex Remand
May 20, 2021
Authored and Edited by Sneha Nyshadham; Caitlin E. Fowler; Elizabeth D. Ferrill
In New Vision Gaming & Dev., Inc. v. SG Gaming, Inc., No. 2020-1399 (Fed. Cir. May 13, 2021), the Federal Circuit vacated two covered-business method review final written decisions finding that all of the claims were patent ineligible under 35 U.S.C. § 101 and remanded for further proceedings.
The Court granted New Vision’s request to vacate and remand the Board’s decision in light of the Court’s decision in Arthrex, Inc. v. Smith & Nephew, Inc., 941 F.3d 1320 (Fed. Cir. 2019) finding that New Vision did not waive the challenge because the Arthrex decision issued after the Board’s final written decision.
Judge Newman filed an opinion concurring in part and dissenting in part. Judge Newman agreed that the Board’s decision must be vacated under Arthrex. However, Judge Newman argued that the Court should first determine whether the forum selection clause in the parties’ license agreement barred SG Gaming from pursuing CBM review before deciding whether remand is appropriate. Judge Newman argued that this is a threshold issue that should be determined because if the parties are committed to resolving any disputes in Nevada, there is no basis for new PTAB proceedings on remand.
United States Court of Appeals for the Federal Circuit (CAFC), Patent Trial and Appeal Board (PTAB), patentable subject matter, Arthrex v. Smith & Nephew
Copyright © 2021 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Conference
19th Annual Forum on Pharma & Biotech Patent Litigation in Europe
May 19-20, 2026
Amsterdam
Panel Discussion
May 5, 2026
London
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.